Drug Trial Radar · NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
675
Planned (sponsor's estimate)
Start
Oct 8, 2025
Primary completion
Dec 7, 2029
Study completion Aug 6, 2032
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Sep 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.
Conditions
- Non-small Cell Lung Cancer
Interventions
CalderasibDrug
Administered as an oral tablet
Pembrolizumab (+) Berahyaluronidase alfaBiological
Administered as a SC injection
PemetrexedDrug
Administered as an IV Infusion
CisplatinDrug
Administered as an IV Infusion
CarboplatinDrug
Administered as an IV Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS) in Participants with Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥1%Time frame: Up to approximately 48 months
Locations
226 sites in 30 countries. Site status is shown where the registry gives one.
Central Alabama Research ( Site 0108)
Birmingham, Alabama · Recruiting
Beverly Hills Cancer Center ( Site 0142)
Beverly Hills, California · Recruiting
University of Connecticut Health Center ( Site 0130)
Farmington, Connecticut · Recruiting
Stamford Hospital ( Site 0126)
Stamford, Connecticut · Recruiting
The Oncology Institute of Hope and Innovation ( Site 0161)
Fort Lauderdale, Florida · Recruiting
Mount Sinai Cancer Center ( Site 0137)
Miami Beach, Florida · Completed
Low Country Cancer Care ( Site 0156)
Savannah, Georgia · Recruiting
Indiana University Health Arnett Cancer Center ( Site 0116)
Lafayette, Indiana · Recruiting
New England Cancer Specialists ( Site 0139)
Westbrook, Maine · Recruiting
Minneapolis VA Medical Center ( Site 0145)
Minneapolis, Minnesota · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0152)
Hackensack, New Jersey · Recruiting
New York Oncology Hematology, P.C. ( Site 0119)
Albany, New York · Recruiting
Wilmot Cancer Institute ( Site 0141)
Rochester, New York · Recruiting
St. Charles Health System, Inc ( Site 0146)
Bend, Oregon · Recruiting
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111)
Lancaster, Pennsylvania · Recruiting
Hematology Oncology Associates of Fredericksburg ( Site 9550)
Fredericksburg, Virginia · Recruiting
Bon Secours Cancer Institute at St. Francis ( Site 0148)
Midlothian, Virginia · Recruiting
Blue Ridge Cancer Care ( Site 0144)
Roanoke, Virginia · Recruiting
WVU Cancer Institute ( Site 0153)
Morgantown, West Virginia · Recruiting
Hospital Italiano de Cordoba ( Site 0308)
Córdoba, Argentina · Recruiting
CEMAIC ( Site 0309)
Córdoba, Argentina · Recruiting
Instituto Alexander Fleming ( Site 0311)
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clinicas Mar del Plata ( Site 0300)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Genesis Care- Campbelltown ( Site 2907)
Campbelltown, New South Wales, Australia · Recruiting
Northern Beaches Hospital ( Site 2905)
Frenchs Forest, New South Wales, Australia · Recruiting
The Prince Charles Hospital ( Site 2903)
Brisbane, Queensland, Australia · Recruiting
Mater Hospital Brisbane ( Site 2906)
South Brisbane, Queensland, Australia · Recruiting
Peninsula & South Eastern Haematology and Oncology Group ( Site 2908)
Frankston, Victoria, Australia · Recruiting
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 1001)
Vienna, Austria · Recruiting
Klinikum Klagenfurt am Wörthersee ( Site 1002)
Klagenfurt, Carinthia, Austria · Recruiting
Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 1005)
Graz, Styria, Austria · Recruiting
Clinical Chc Montlégia ( Site 3901)
Liège, Belgium · Recruiting
Algemeen Ziekenhuis Klina ( Site 3904)
Brasschaat, Antwerpen, Belgium · Recruiting
CHU Helora - Hôpital de La Louvière - Site Jolimont ( Site 3900)
La Louvière, Hainaut, Belgium · Recruiting
Ziekenhuis Oost-Limburg, Campus St.-Jan ( Site 3903)
Genk, Limburg, Belgium · Recruiting
VITAZ ( Site 3902)
Sint-Niklaas, Oost-Vlaanderen, Belgium · Recruiting
IBCC - Núcleo de Pesquisa e Ensino ( Site 0417)
São Paulo, Brazil · Recruiting
CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA ( Site 0412)
Fortaleza, Ceará, Brazil · Recruiting
Hospital Santa Rita de Cassia ( Site 0403)
Vitória, Espírito Santo, Brazil · Recruiting
Real Hospital Portugues ( Site 0418)
Recife, Pernambuco, Brazil · Recruiting
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.